Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
about
Immunotherapy of systemic sclerosisPharmacology and rationale for imatinib in the treatment of sclerodermaOptimizing reduced-intensity conditioning regimens for myeloproliferative neoplasms.Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host DiseaseImatinib and dasatinib as salvage therapy for sclerotic chronic graft-vs-host diseaseProfibrotic TGFβ responses require the cooperative action of PDGF and ErbB receptor tyrosine kinases.The impact of Fli1 deficiency on the pathogenesis of systemic sclerosisTransforming growth factor beta as a therapeutic target in systemic sclerosis.Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease.Phototherapy for the treatment of cutaneous graft versus host disease.A review of late complications of allogeneic hematopoietic stem cell transplantations.Development of severe sclerotic chronic GVHD during treatment with dasatinib.Is imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease?Prognostic factors for outcomes of allogeneic stem cell transplantation in chronic phase chronic myeloid leukemia in the era of tyrosine kinase inhibitors.Tirosin kinase inhibitors in chronic graft versus host disease: from bench to bedside.Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: a multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC)Risk stratification of organ-specific GVHD can be improved by single-nucleotide polymorphism-based risk models
P2860
Q24634395-BEF2FBE8-DA72-4C63-9904-573D9C304801Q26825153-03FDFAAD-9D2F-4924-8D01-5E59C917D0B9Q33771667-FEFD3150-4662-454B-B4D5-E08A95A72E02Q35566387-AF068876-F8AE-4BAF-8745-F2B2DC7DE133Q36220062-425F17BB-4371-4B08-8D1D-278A58651522Q37075998-27D865A1-67E4-4B85-9FCB-FD4D03D2B94CQ37245959-83A6E066-AC5E-403C-9874-025650C778E7Q37305155-C5C04D5B-D7F1-47EB-8DB6-CCF7E06826E5Q37428739-007192BA-11E2-4AE6-B88A-A57BCFE6A2BCQ37511121-3C8A952E-193B-4A50-9E02-F0D43D203E1DQ38258802-BE42B15E-0209-4210-8E5C-384F19404F6DQ40115697-2C0925BA-8110-4F5E-BE61-B90B2F493757Q43198288-573CF387-F10D-4F88-A9EA-EC877329803CQ46104083-A432CACA-F8A3-4F37-BCE9-A518A4D2FE1AQ46737739-CE8C77E2-484F-4ADA-8C9D-2732683D1E00Q54546815-1EA39995-73F2-42B7-A7B2-BBEB77977754Q56576062-3EDD53D5-39CE-4AA3-BA40-F08AE56A6119Q57910691-960777D8-AC90-4C6C-8FE7-873123988350
P2860
Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Efficacy of imatinib mesylate ...... sclerodermatous chronic GVHD.
@en
Efficacy of imatinib mesylate ...... sclerodermatous chronic GVHD.
@nl
type
label
Efficacy of imatinib mesylate ...... sclerodermatous chronic GVHD.
@en
Efficacy of imatinib mesylate ...... sclerodermatous chronic GVHD.
@nl
prefLabel
Efficacy of imatinib mesylate ...... sclerodermatous chronic GVHD.
@en
Efficacy of imatinib mesylate ...... sclerodermatous chronic GVHD.
@nl
P2093
P2860
P356
P1476
Efficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHD
@en
P2093
P2860
P2888
P304
P356
10.1038/BMT.2008.252
P407
P577
2008-09-01T00:00:00Z